FDA Grants Breakthrough Status to En Carta’s Single-Use Lyme Test
En Carta Diagnostics, a start-up focused on molecular diagnostics kits, has announced that its EC Pocket Lyme test has received Breakthrough Device Designation from the US Food and Drug Administration (FDA) – a regulatory milestone reserved for innovations that could materially improve the diagnosis or treatment of serious conditions.
The ambition behind EC Pocket Lyme is clear: make early Lyme detection more accurate and more accessible, particularly at the stage when patients present with signs of a tick bite or erythema migrans (EM) – the well-known “bullseye” rash that can indicate Lyme disease.
A skin-level approach to finding Borrelia
Unlike many current diagnostic pathways that rely heavily on symptom observation and antibody responses that may take time to develop, EC Pocket Lyme is designed to detect Borrelia bacteria directly.
The test targets interstitial fluid samples taken from the skin – specifically from people showing tick-bite indicators or EM – aiming to identify infection earlier, when treatment can be most effective.
En Carta says results from EC Pocket Lyme can be combined with other tests and clinical findings, supporting clinicians as they piece together a clearer diagnostic picture of Borrelia infections that cause Lyme disease.
Designed for affordability, accessibility, and wide distribution
A notable part of the product concept is its practicality: EC Pocket Lyme has been designed with affordability and accessibility in mind, delivered in a single-use cassette format intended for wide distribution.
That format signals a push toward making testing simpler to deploy – an important consideration for conditions where timing and access can influence outcomes.
Why earlier diagnosis matters
Lyme disease is an infection transmitted through tick bites, and early diagnosis is often challenging.
Current diagnostics commonly include a mix of visual assessment of symptoms and antibody detection tests – approaches that can be limited, particularly early on, when the immune system may not yet have produced antibodies at detectable levels.
This is where the unmet need is most acute. En Carta points to the reality that if Lyme disease is not treated early, it can progress to serious illness and, in severe cases, can be fatal – reinforcing the urgency for improved early-stage diagnostics.
Breakthrough Device Designation: what it changes
The FDA’s Breakthrough Device Designation is reserved for products that may offer meaningful advantages for very serious diseases.
For En Carta, the designation brings more than recognition: the FDA will now provide priority review for EC Pocket Lyme and enable increased communication with FDA experts, supporting a faster, more collaborative regulatory journey.
In a statement, En Carta’s co-founder and chief technology officer described the designation as “a pivotal moment,” adding that it strengthens their regulatory path through closer FDA collaboration and accelerates their route to market, so patients can benefit sooner.
A growing public health backdrop
The announcement also lands amid a longstanding trend. Cases of Lyme disease have been increasing for more than four decades, and the scale is significant: the United States is estimated to see around 476,000 new Lyme cases each year.
Against that backdrop, tools that improve early detection – especially at the point when tick-bite signs or EM appear – could help shift outcomes for large numbers of people.
Conclusion
With Breakthrough Device Designation now secured, En Carta Diagnostics has taken a major step toward advancing EC Pocket Lyme, a single-use, widely distributable test designed to detect Borrelia directly from skin interstitial fluid in people with early signs such as tick bites or erythema migrans.
As Lyme cases continue to rise in the US and early diagnosis remains difficult using today’s symptom-and-antibody-led approaches, the FDA’s decision signals both the seriousness of the unmet need and the potential impact of faster, more accessible diagnostic options – alongside an accelerated, higher-support regulatory pathway that could bring this test to patients sooner.
News Credits: En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
Things you may also like: